Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMJ5MPG)

Drug Name

BDC-1001 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carcinoembryonic antigen CEA (CD66e)	TTY6DTE	CEAM5_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Carcinoembryonic antigen CEA (CD66e)	DTT	CEACAM5	5.812	11.49	6.112	6.957

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Solid tumour/cancer

ICD Disease Classification

2A00-2F9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Carcinoembryonic antigen CEA (CD66e)	DTT	CEACAM5	6.68E-91	0.29	1.07

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04278144) A First-in-human Study Using BDC-1001 in Advanced HER2-Expressing Solid Tumors. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Bolt Biotherapeutics.